They are different ingredients in different products
Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both glucose-dependent insulinotropic polypeptide and GLP-1 receptors according to Zepbound labeling DailyMed Zepbound label. That mechanism difference does not mean one product is automatically the right choice for every patient.
For weight management, patients usually encounter product names such as Wegovy for semaglutide and Zepbound for tirzepatide. Other products with the same ingredients may have different approved indications. The product label, not the ingredient name alone, determines the approved indication, route and dosing instructions.
Why simple rankings can mislead
Many searches frame this comparison as one drug against another. That framing leaves out the clinical details. Product labels cover different products, studied populations, dosage forms, indications and warnings. Insurance access, supply, other prescriptions, side effects and patient preference can also change the discussion.
A careful comparison should start with the exact product being considered. Then it should move to the patient’s medical history and follow-up plan. Broad ranking language can sound decisive while skipping the facts a clinician actually needs.
Routes and labeling are product-specific
Current Wegovy labeling includes semaglutide injection for subcutaneous use and semaglutide tablets for oral use DailyMed Wegovy label. Current Zepbound labeling describes tirzepatide injection for subcutaneous use DailyMed Zepbound label.
That matters when people compare online programs. An oral semaglutide tablet with FDA-approved labeling is different from a compounded oral or dissolving preparation. A tirzepatide injection under Zepbound labeling is different from a compounded tirzepatide preparation. Ask for the product name, route, dosage form and approval status in plain language.
Approved uses are not interchangeable
| Product example | Ingredient | Route in current label | Weight-related label context |
|---|---|---|---|
| Wegovy | Semaglutide | Injection and tablet | Wegovy injection is labeled for weight reduction and long-term maintenance in adults and pediatric patients aged 12 years and older with obesity, and adults with overweight plus at least one weight-related condition. Wegovy tablets are labeled for adult weight reduction and long-term maintenance in adults with obesity or overweight plus at least one weight-related condition. |
| Zepbound | Tirzepatide | Injection | Weight reduction and long-term maintenance for labeled adult populations, with diet and physical activity. |
| Rybelsus | Semaglutide | Tablet | Official labeling is for adults with type 2 diabetes, including glycemic-control use and reduction of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for events. It is not a general weight-management label DailyMed Rybelsus label. |
A clinician may discuss options using the patient’s medical history, contraindications, other medications, goals, tolerability, access and product labeling.
Warnings and contraindications deserve more than a skim
Both Wegovy and Zepbound labels include a boxed warning about thyroid C-cell tumors observed in rodents and contraindications for patients with a personal or family history of medullary thyroid carcinoma or MEN 2 Wegovy label Zepbound label. Their labels also discuss gastrointestinal adverse reactions and other warnings that may affect follow-up.
Patients should tell the clinician about past pancreatitis, gallbladder disease, kidney problems, insulin, sulfonylureas or other diabetes medicines, pregnancy plans, contraception and any severe stomach symptoms. Pregnancy and contraception can affect the comparison. Wegovy labeling includes discontinuation guidance at least 2 months before a planned pregnancy for weight reduction or cardiovascular risk reduction. Zepbound labeling says it may reduce oral hormonal contraceptive efficacy and includes guidance to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation Wegovy label Zepbound label. The goal is not to memorize the label. It is to give the clinician enough information to decide what is appropriate and what needs monitoring.
How to compare options in a clinical visit
- Which product are we discussing, and is it FDA-approved or compounded?
- What indication and route apply to this exact product?
- What contraindications or warnings in the label matter for my history?
- How will side effects, refills and follow-up be handled?
- What happens if insurance, availability or pharmacy fulfillment changes?
For the next step, read what determines GLP-1 eligibility and FDA-approved vs compounded GLP-1 medications.
Common questions
Is tirzepatide always preferred over semaglutide?
That is not a safe blanket claim. They are different ingredients with different product labels, trial programs and patient considerations. A clinician should compare product-specific evidence and patient-specific risks.
Is semaglutide available as an FDA-approved oral product?
Yes, specific semaglutide tablets are FDA-approved, including Wegovy tablets and Rybelsus tablets. Their indications and product labels differ.
Does Zepbound contain semaglutide?
No. Zepbound contains tirzepatide. Wegovy contains semaglutide.
Can I switch between semaglutide and tirzepatide on my own?
No. Switching prescription medications should be handled by a licensed clinician who can review product labeling, timing, side effects, other medications and medical history.
References
- DailyMed: Wegovy prescribing information
- DailyMed: Zepbound prescribing information
- DailyMed: Rybelsus and Ozempic tablets prescribing information
Sources checked on October 1, 2026.